Basilea: Submission of marketing authorization application for Alitretinoin to Swiss regulatory authority

02-Oct-2007

Basilea Pharmaceutica Ltd. announced the submission of a marketing authorization application to Swissmedic for its investigational drug alitretinoin. The submission supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema. Basilea also announced the appointment of Mr. Hans Christian Rohde as Global Head of Commercial Operations.

The marketing authorization application seeks approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema (CHE) and is based on a clinical program comprising almost 2000 patients.

Recently, marketing authorization applications for alitretinoin in severe refractory CHE have been submitted to various EU member states.

Basilea Pharmaceutica Ltd. also announced the appointment of Mr. Hans Christian Rohde as Global Head of Commercial Operations. This new appointment will further expand Basilea's capabilities to support its product launches and future company growth.

Mr. Rohde has held senior positions in international marketing, sales and general management with Novo Nordisk, Biogen and Serono both in Europe and the United States. He was most recently a Global Therapeutic Area Head, Corporate Marketing at Merck Serono. He was responsible for numerous successful global product launches during his 19 year career in the pharmaceutical industry. Mr. Rohde will join Basilea's Management team shortly. Basilea announces that Mr. Nicholas Benedict, Head of Commercial Operations, has decided to leave the company for personal reasons. Mr. Benedict made a significant contribution to setting up Basilea's commercial infrastructure to prepare for the imminent product launches and Basilea wishes him much success for the future.

https://www.bionity.com/en/news/70924/basilea-submission-of-marketing-authorization-application-for-alitretinoin-to-swiss-regulatory-authority.html